HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives

This article was originally published in The Pink Sheet Daily

Executive Summary

In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.

You may also be interested in...

Ruining The Mood, US FDA Says Glycerin, Oleate Cream Not Approved As OTC Contraceptive

Smart Women’s Choice promotes its namesake brand topicals with claims including “One hundred percent hormone-free, completely safe, natural birth control that cannot fail when used as directed and causes no harmful side effects,” FDA warning says.

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.

Recommendation For OTC Buprenorphine Joins Opioid Abuse Epidemic Discussion

Boston University researchers recommend allowing pharmacists to dispense buprenorphine without prescriptions to expand access among the 2m consumers with opioid use disorder and help reduce the estimated 130 overdose deaths each day in the US. "It is important to attempt to address the opioid epidemic in new, effective, and safe ways. Increasing access to buprenorphine, a relatively safe medication, without a prescription could prove helpful for treating persons with OUD," say Payel Jhoom Roy and Michael Stein.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts